A pivotal role for Mcl-1 in Bortezomib-induced apoptosisPODAR, K; GOUILL, S. L; ANDERSON, K. C et al.Oncogene (Basingstoke). 2008, Vol 27, Num 6, pp 721-731, issn 0950-9232, 11 p.Article

Bortezomib-induced skin lesionsAGTEROF, Mariëtte J; BIESMA, Douwe H.The New England journal of medicine. 2005, Vol 352, Num 24, issn 0028-4793, p. 2534Article

Gα_12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulationYOON MEE YANG; LEE, Sanghwan; CHANG WON NAM et al.Carcinogenesis (New York. Print). 2010, Vol 31, Num 7, pp 1230-1237, issn 0143-3334, 8 p.Article

The role of proteasome inhibitors in solid tumors : Proteasome inhibitionPARK, David J; LENZ, Heinz-Josef.Annals of medicine (Helsinki). 2004, Vol 36, Num 4, pp 296-303, issn 0785-3890, 8 p.Article

Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade)ARPINATI, M; CHIRUMBOLO, G; NICOLINI, B et al.Bone marrow transplantation (Basingstoke). 2009, Vol 43, Num 3, pp 253-259, issn 0268-3369, 7 p.Article

Amyloid myopathy: a therapeutic trial for the rare and underdiagnosed myopathy with bortezomibSHIGA, Kensuke; MIZUTANI, Reiko; ISAYAMA, Reina et al.Journal of neurology. 2010, Vol 257, Num 12, pp 2091-2093, issn 0340-5354, 3 p.Article

Novel Proteasome Inhibitors to Overcome Bortezomib ResistanceRUSCHAK, Amy M; SLASSI, Malik; KAY, Lewis E et al.Journal of the National Cancer Institute. 2011, Vol 103, Num 13, pp 1007-1017, issn 0027-8874, 11 p.Article

Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapyDICK, Lawrence R; FLEMING, Paul E.Drug discovery today. 2010, Vol 15, Num 5-6, pp 243-249, issn 1359-6446, 7 p.Article

Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal diseaseWECHALEKAR, Ashutosh D; LACHMANN, Helen J; OFFER, Mark et al.Haematologica (Roma). 2008, Vol 93, Num 2, pp 295-298, issn 0390-6078, 4 p.Article

Incorporating bortezomib into upfront treatment for multiple myeloma : early results of total therapy 3BARLOGIE, Bart; ANAISSIE, Elias; BOLEJACK, Vanessa et al.British journal of haematology. 2007, Vol 138, Num 2, pp 176-185, issn 0007-1048, 10 p.Article

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment StrategyWRIGHT, John J.Clinical cancer research (Print). 2010, Vol 16, Num 16, pp 4094-4104, issn 1078-0432, 11 p.Article

Can Tumor Growth Be Further Inhibited by Combining Drugs Such as Bortezomib with Image-guided Interventional Oncologic Procedures?NAHUM GOLDBERG, S.Radiology. 2008, Vol 248, Num 2, pp 323-325, issn 0033-8419, 3 p.Article

Bortezomib: clinical profile in lymphoproliferative malignanciesO'CONNOR, Owen A.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 6, pp 18-24, issn 1359-6349, 7 p.Conference Paper

Cardiotoxicity of the Anticancer Therapeutic Agent BortezomibNOWIS, Dominika; MACZEWSKI, Michał; BUGAJSKI, Marek et al.The American journal of pathology. 2010, Vol 176, Num 6, pp 2658-2668, issn 0002-9440, 11 p.Article

Bortezomib-induced histiocytoid Sweet syndromeMURASE, Jenny E; WU, Jashin J; THEATE, Ivan et al.Journal of the American Academy of Dermatology. 2009, Vol 60, Num 3, pp 496-497, issn 0190-9622, 2 p.Article

Bortezomib-induced sweet syndromeKNOOPS, Laurent; JACQUEMAIN, Aurore; TENNSTEDT, Dominique et al.British journal of haematology. 2005, Vol 131, Num 2, issn 0007-1048, p. 142Article

Bortezomib in multiple myeloma: Treatment approach and outcomesHAROUSSEAU, Jean-Luc.European journal of cancer. Supplement (1990). 2004, Vol 2, Num 6, pp 12-17, issn 1359-6349, 6 p.Conference Paper

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse EventsARASTU-KAPUR, Shirin; ANDERL, Janet L; KIRK, Christopher J et al.Clinical cancer research (Print). 2011, Vol 17, Num 9, pp 2734-2743, issn 1078-0432, 10 p.Article

Approval summary for bortezomib for injection in the treatment of multiple myelomaBROSS, Peter F; KANE, Robert; LEIGHTON, John et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 3954-3964, issn 1078-0432, 11 p., 1Article

Velcade® (bortezomib) dans le traitement du myélome multiple : résultats des essais cliniquesFACON, Thierry.Hématologie (Montrouge). 2004, Vol 10, pp 9-12, issn 1264-7527, 4 p., NS3Conference Paper

Correction: Bortezomib Sensitizes Cells to ER StressCancer research (Chicago, Ill.). 2009, Vol 69, Num 4, issn 0008-5472, p. 1695Article

Phase I study of bortezomib in refractory or relapsed acute leukemiasCORTES, Jorge; THOMAS, Deborah; WRIGHT, John et al.Clinical cancer research. 2004, Vol 10, Num 10, pp 3371-3376, issn 1078-0432, 6 p.Article

Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction : Targeting the Ubiquitin-Proteasome Pathway - Current Perspectives and Future DirectionsBIYIN CAO; JIE LI; XINLIANG MAO et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 18, pp 3190-3200, issn 1381-6128, 11 p.Article

The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of BortezomibCVEK, Boris; DVORAK, Zdenek.Current pharmaceutical design (Print). 2011, Vol 17, Num 15, pp 1483-1499, issn 1381-6128, 17 p.Article

Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytesPISCIANZ, Elisa; CUZZONI, Eva; DE IUDICIBUS, Sara et al.International immunopharmacology (Print). 2011, Vol 11, Num 12, pp 2242-2245, issn 1567-5769, 4 p.Article